Crown Bioscience Center of Excellence for Oncology in San Diego Expands Services
August 18, 2016
Santa Clara, Calif., Aug. 16, 2016 — Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has expanded its oncology services with new models, cell lines and assays at its Center of Excellence for Oncology in San Diego.
The new services introduce a range of platforms for the evaluation of immuno-oncology programs, while also adding new technologies for traditional oncology agents. Responding to the global focus on immuno-oncology, CrownBio has added a broad portfolio of highly characterized syngeneic in vivo services, and at the same time expanded supporting flow cytometry laboratories for both syngeneic and humanized PDX studies.
Mike Prosser, CrownBio’s general manager of European and North American operations, commenting on the recently announced site expansion and new offering, said: “Following the recent investment in our U.S. site, we now have the capability to offer a significantly extended range of services, from in vitro screening to later stage translational studies, including avatar clinical trials (HuTrials™) with Humanized NSG™ xenografts to evaluate the efficacy of anticancer immunotherapy before entering the clinic.”
CrownBio has also developed new PDX derived cell lines to enrich the company’s PrimePanel™ collection with primary cells from Caucasian, pretreated and metastatic tumor samples, to help evaluate traditional oncology agents. Additionally, CrownBio has developed expanded 3D-tumor growth assays (3D-TGA) for most indications to provide translational in vitro models aligned to the tumor microenvironment.
“These new services will allow us to provide our clients, leading global biopharmaceutical companies, with local access to a range of platforms, including advanced models that more accurately reflect tumor microenvironments, thereby offering better screening tools for evaluating innovative oncology drug candidates,” said Jean-Pierre Wery, Ph.D., CEO of CrownBio.
For more information about CrownBio’s commitment to furthering oncology and metabolic disease research, visit www.crownbio.com.
PrimePanel™ and HuTrial™ are a trademark of Crown Bioscience International. Humanized NSG™ is a trademark of Jackson Laboratories.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.